PCI Antiplatelet and Anticoagulant Therapy e372 Oral and Intravenous Antiplatelet Agents: Recommendations e372 GP IIb/IIIa Inhibitors: Recommendations e373 5.1.2.3. Anticoagulant Therapy in Patients Undergoing PCI: Recommendations e374 Timing of Urgent CABG in Patients With NSTE-ACS in Relation to Use of Antiplatelet Agents: Recommendations e375 Late Hospital Care, Hospital Discharge, and Posthospital Discharge Care e376 General Principles (Cardioprotective Therapy and Symptom Management) e376 Medical Regimen and Use of Medications at Discharge: Recommendations e376 Late Hospital and Posthospital Oral Antiplatelet Therapy: Recommendations e376 6.2.2. Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTE-ACS e378 Platelet Function and Genetic Phenotype Testing e379 Risk Reduction Strategies for Secondary Prevention e379 Cardiac Rehabilitation and Physical Activity: Recommendation e379 6.3.2. Patient Education: Recommendations e380 6.3.3. Pneumococcal Pneumonia: Recommendation e380 6.3.4. NSAIDs: Recommendations e380 6.3.5. Hormone Therapy: Recommendation e380 Antioxidant Vitamins and Folic Acid: Recommendations e381 Plan of Care for Patients With NSTE-ACS: Recommendations e381 Systems to Promote Care Coordination e382 7. Special Patient Groups e382 NSTE-ACS in Older Patients: Recommendations e382 7.2. HF: Recommendations e383 7.2.1. Arrhythmias e383 7.2.2. Cardiogenic Shock: Recommendation e386 7.3. Diabetes Mellitus: Recommendation e386 7.3.1. Adjunctive Therapy e387 7.4. Post CABG: Recommendation e387 Perioperative NSTE-ACS Related to Noncardiac Surgery: Recommendations e387 7.6. CKD: Recommendations e388 7.6.1. Antiplatelet Therapy e388 7.7. Women: Recommendations e389 Anemia, Bleeding, and Transfusion: Recommendations e389 7.9. Thrombocytopenia e390 Cocaine and Methamphetamine Users: Recommendations e390 7.11. Vasospastic (Prinzmetal) Angina: Recommendations e391 7.12. ACS With Angiographically Normal Coronary Arteries: Recommendation e392 Stress (Takotsubo) Cardiomyopathy: Recommendations e392 7.14. Obesity e393 7.15. Patients Taking Antineoplastic/ Immunosuppressive Therapy e393 Quality of Care and Outcomes for ACS Use of Performance Measures and Registries e393 Use of Performance Measures and Registries: Recommendation e393 Summary and Evidence Gaps e393 References e394 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) e414 Appendix 2. 